by GOAI

由GOAI生成

Share To

分享到

Sensorion has announced a reserved offering of $71.9 million aimed at advancing its gene therapy pipeline. The financing includes a €20 million strategic investment from Sanofi, alongside €40 million contributed by both existing and new investors. Key participants in the funding round include Artal, advised by Invus, Redmile Group, Cormorant Asset Management, and Sofinnova..

Sensorion 宣布了一项 7190 万美元的定向增发，旨在推进其基因治疗管线。此次融资包括赛诺菲（Sanofi）提供的 2000 万欧元战略投资，以及现有和新投资者共同贡献的 4000 万欧元。主要参与本轮融资的包括由 Invus 提供咨询的 Artal、Redmile Group、Cormorant Asset Management 和 Sofinnova。

The funds are expected to support Sensorion’s ongoing efforts to expand its portfolio of gene therapies targeting inner ear disorders. This financial backing reflects continued interest from prominent investors in the biotechnology sector and highlights the growing focus on innovative treatments for hearing-related conditions..

预计这笔资金将支持Sensorion继续扩展其针对内耳疾病基因疗法组合的努力。此次财务支持反映了生物技术领域知名投资者的持续兴趣，并突显了对听力相关疾病创新治疗日益增长的关注。

Newsflash | Powered by GeneOnline AI

新闻快讯 | 由GeneOnline AI提供支持

Source: GO-AI-ne1

来源：GO-AI-ne1

For any suggestion and feedback, please contact us.

如有任何建议和反馈，请联系我们。

Date: Got it! Please provide the date you’d like me to format.

日期：明白了！请提供您想要格式化的日期。

©www.geneonline.com All rights reserved. Collaborate with us:

©www.geneonline.com 版权所有。与我们合作：

[email protected]

电子邮件地址

Author

作者

GOAI

GOAI

Related Post

相关内容